Login to Your Account

Purdue, Transcept Going DTC with Insomnia Drug Intermezzo

By Marie Powers
Staff Writer

Wednesday, November 28, 2012
Purdue Pharmaceutical Products LP will commit $19 million to a six-month direct-to-consumer (DTC) advertising program for Intermezzo (zolpidem tartrate), the insomnia drug developed by Transcept Pharmaceuticals Inc., which is kicking in an additional $10 million toward the effort.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription